presented the results of a Phase II RCT evaluating a Jak inhibitor with selectivity ... Treatment for rheumatoid arthritis (RA) has evolved over the last 15 years with early aggressive treatment ...

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first ...

The use of JAK vs TNF inhibitors shows no significant increase in the incidence of major adverse cardiovascular events in ...

Positive data in December from Rigel Pharmaceuticals' phase 2 trial of R788, an oral rheumatoid arthritis ... an inhibitor of a cytoplasmic (or 'non–membrane associated') tyrosine kinase ...

Advances in knowledge of the pathogenesis of rheumatoid ... Of the kinase inhibitors in the drug development pipeline, the upstream Janus kinase (JAK) and spleen tyrosine kinase (Syk) targets ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

We're excited now, we've got a brand new oral tyrosine kinase inhibitor, zongertinib. The exciting data that we'll be presenting here at the meeting is, first of all, that this drug has a very ...

inhibitor tofacitinib (Xeljanz) with an investigational oral drug targeting a different type of kinase enzyme was more effective against rheumatoid arthritis (RA) than tofacitinib alone in a phase ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...